Gibbs Lab
@gibbslab.bsky.social
We focus on registry and translational (ctDNA, organoid) cancer research
🏢 WEHI (Walter and Eliza Hall Institute)
Melbourne, Australia
🏢 WEHI (Walter and Eliza Hall Institute)
Melbourne, Australia
Fabulous work by the #gibbslab at ESMO Asia 2024 last weekend! 🌟
🔍 Lab head Prof. Peter Gibbs co-chaired a session on shaping the future of metastatic colorectal cancer. His own presentation explored novel strategies he has being investigating for the treatment and management of mCRC.
🔍 Lab head Prof. Peter Gibbs co-chaired a session on shaping the future of metastatic colorectal cancer. His own presentation explored novel strategies he has being investigating for the treatment and management of mCRC.
December 12, 2024 at 6:13 AM
Fabulous work by the #gibbslab at ESMO Asia 2024 last weekend! 🌟
🔍 Lab head Prof. Peter Gibbs co-chaired a session on shaping the future of metastatic colorectal cancer. His own presentation explored novel strategies he has being investigating for the treatment and management of mCRC.
🔍 Lab head Prof. Peter Gibbs co-chaired a session on shaping the future of metastatic colorectal cancer. His own presentation explored novel strategies he has being investigating for the treatment and management of mCRC.
10 posters presented Gibbs Lab clinical research studies including:
🔍 Utilising the TRACC registry, Dr Grace Kim is investigating how targeted testing of mismatch repair and mutations in colorectal patients could be cost-effective for identifying appropriate future therapies.
🔍 Utilising the TRACC registry, Dr Grace Kim is investigating how targeted testing of mismatch repair and mutations in colorectal patients could be cost-effective for identifying appropriate future therapies.
December 2, 2024 at 2:43 AM
10 posters presented Gibbs Lab clinical research studies including:
🔍 Utilising the TRACC registry, Dr Grace Kim is investigating how targeted testing of mismatch repair and mutations in colorectal patients could be cost-effective for identifying appropriate future therapies.
🔍 Utilising the TRACC registry, Dr Grace Kim is investigating how targeted testing of mismatch repair and mutations in colorectal patients could be cost-effective for identifying appropriate future therapies.
#GibbsLab research was well represented at AGITG ASM 2024 last week. 🌟
Prof. Jeanne Tie provided a key update on the early-stage lower GI trial, DYNAMIC – Rectal, looking at management of BRAF V600E mutant colorectal cancer through the Australian lens.
Prof. Jeanne Tie provided a key update on the early-stage lower GI trial, DYNAMIC – Rectal, looking at management of BRAF V600E mutant colorectal cancer through the Australian lens.
December 2, 2024 at 2:42 AM
#GibbsLab research was well represented at AGITG ASM 2024 last week. 🌟
Prof. Jeanne Tie provided a key update on the early-stage lower GI trial, DYNAMIC – Rectal, looking at management of BRAF V600E mutant colorectal cancer through the Australian lens.
Prof. Jeanne Tie provided a key update on the early-stage lower GI trial, DYNAMIC – Rectal, looking at management of BRAF V600E mutant colorectal cancer through the Australian lens.
Dr Shehara Mendis received the Early Career Researcher Award, for her outstanding work in gastrointestinal cancer! She gave an update on BIOMARCER-2, a lower GI clinical trial which aims to demonstrate progression free survival benefit in patients receiving anti-EGFR treatment in 2nd+ line setting.
December 2, 2024 at 2:41 AM
Dr Shehara Mendis received the Early Career Researcher Award, for her outstanding work in gastrointestinal cancer! She gave an update on BIOMARCER-2, a lower GI clinical trial which aims to demonstrate progression free survival benefit in patients receiving anti-EGFR treatment in 2nd+ line setting.